Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs
Breast cancer is a major health challenge for women worldwide, and human epidermal growth factor receptor 2 (HER-2)-positive breast cancers have a relatively high incidence and are highly aggressive. Targeted therapeutic agents, represented by trastuzumab, have been effective in improving the surviv...
Saved in:
Main Authors: | Xiang Zhang, Yulian Yin, Qiuting Yu, Xinlin Chen, Yiqin Cheng |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1492203/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The association of BMI and subclinical myocardial dysfunction in breast cancer patients after single or dual anti-HER2 targeted therapy
by: Feng Zhang, et al.
Published: (2024-12-01) -
A multicenter retrospective study of early cardiac toxicity in operable breast cancer patients receiving concurrent dual or mono anti-HER2 therapy with postoperative radiation therapy
by: Jing Yang, et al.
Published: (2025-02-01) -
Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer
by: Hanghang Ma, et al.
Published: (2025-02-01) -
Nomograms for predicting recurrence of HER2‐positive breast cancer with different HR status based on ultrasound and clinicopathological characteristics
by: Xudong Zhang, et al.
Published: (2024-09-01) -
Investigation of cardiotoxic effects of marbofloxacin
by: Devran Coşkun, et al.